Skip to main content
. 2024 Nov 27;12(11):e010069. doi: 10.1136/jitc-2024-010069

Figure 6. VEGFi plus anti-PD-1 exerts clinical benefit in refractory OCCC. (A) Line chart showing dynamic changes of cancer antigens of persistent OCCC case 1 and representative CT images who received VEGF inhibition plus anti-PD1 during the course of disease. (B) Line chart showing dynamic changes of cancer antigens of recurrent OCCC case 2 and representative PET-CT and CT images who received VEGF inhibition plus anti-PD1 during the course of disease. (C) OCCC case 3: metastatic patients with OCCC received anti-PD1/CTLA4 treatment. (D) Graphical abstract. OCCC, ovarian clear cell carcinoma.

Figure 6